Stay updated on Lorlatinib in ROS1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lorlatinib in ROS1+ NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The record history now shows a new Revision: v3.5.4, replacing the prior Revision: v3.5.3. This represents a metadata update to the study record's history rather than a change to the study content.
    Difference
    0.1%
    Check dated 2026-05-14T23:07:32.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page footer’s software revision indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” a change related to the ClinicalTrials.gov site build rather than the underlying study record.
    Difference
    0.1%
    Check dated 2026-04-23T21:52:45.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    A new revision entry, v3.5.2, was added to the Record History and the previous v3.5.0 entry was removed.
    Difference
    0.1%
    Check dated 2026-04-16T12:27:11.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Record History now shows revision v3.5.0 and removes v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-18T21:27:02.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    A new revision entry (v3.4.3) was added to the record history, and an older entry (v3.4.2) was removed.
    Difference
    0.1%
    Check dated 2026-03-11T18:19:36.000Z thumbnail image
  8. Check
    96 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the Record History.
    Difference
    0.8%
    Check dated 2026-02-11T04:49:26.000Z thumbnail image

Stay in the know with updates to Lorlatinib in ROS1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lorlatinib in ROS1+ NSCLC Clinical Trial page.